Scilex Holding Company SCLXW NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - General • US • USD

SharesGrow Score

21/100

0/5 Pass

SharesGrow Intrinsic Value

$2,893.53

+2630381.8%

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Scilex Holding Company (SCLXW) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -452.98%, forward earnings yield 666.67%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.2); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -452.98%).
Forward P/E 0.2 — analysts expect a return to profitability with estimated EPS of $0.73 for FY2027.
Trailing Earnings Yield -452.98% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 666.67% as earnings recover.

Overall SharesGrow Score: 19/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

21/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

35/100

→ Income

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — SCLXW

Valuation Multiples

P/E (TTM)-0.2

Forward P/E0.2

PEG RatioN/A

Forward PEG0.00

P/B Ratio-0.47

P/S Ratio1.51

EV/EBITDA-0.4

Per Share Data

EPS (TTM)$-32.39

Forward EPS (Est.)$0.73

Book Value / Share$-15.49

Revenue / Share$3.48

FCF / Share$2.05

Yields & Fair Value

Earnings Yield-452.98%

Forward Earnings Yield666.67%

Dividend Yield0.00%

SharesGrow IV$2,893.53 (+2630381.8%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2019	-7.8	0.00	0.00	66.07	-
2020	-29.2	0.30	-9.81	58.99	-
2021	-15.1	0.00	-5.96	42.59	-
2022	-22.9	0.31	14.78	14.08	-
2023	-2.3	0.00	-1.54	5.69	-
2024	-1.4	0.03	-0.54	1.83	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2019	$-1.27	$21.03M	$-178.59M	-849.1%
2020	$-0.34	$23.56M	$-47.52M	-201.7%
2021	$-0.67	$31.32M	$-88.42M	-282.4%
2022	$-0.17	$38.03M	$-23.36M	-61.4%
2023	$-0.88	$46.74M	$-114.33M	-244.6%
2024	$-0.56	$56.59M	$-72.81M	-128.7%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.89	$-0.89 – $-0.89	$66M	$66M – $66M	1
2027	$0.73	$0.73 – $0.73	$188.97M	$188.97M – $188.97M	1
2028	$6.78	$6.78 – $6.78	$608.48M	$608.48M – $608.48M	1
2029	$10.90	$10.90 – $10.90	$944.18M	$944.18M – $944.18M	1
2030	$12.58	$12.58 – $12.58	$1.09B	$1.09B – $1.09B	1